Advertisement

Topics

Latest "Mifepristone Cushing Syndrome" News Stories

01:27 EDT 25th June 2017 | BioPortfolio

Here are the most relevant search results for "Mifepristone Cushing Syndrome" found in our extensive news archives from over 250 global news sources.

More Information about Mifepristone Cushing Syndrome on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Mifepristone Cushing Syndrome for you to read. Along with our medical data and news we also list Mifepristone Cushing Syndrome Clinical Trials, which are updated daily. BioPortfolio also has a large database of Mifepristone Cushing Syndrome Companies for you to search.

Showing "Mifepristone Cushing Syndrome" News Articles 1–25 of 2,300+

Extremely Relevant

Cushing Syndrome Market Insights, Epidemiology and Market Forecast 2023 US [Updated: 30052017] Prices from USD $2083

DelveInsight's Cushing Syndrome Market Insights, Epidemiology and Market Forecast 2023 US Reports provides an overview of the disease and global market size of the Cushing Syndrome for the US. It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Cushing Syndrome from 20102023. According to Publisher, the forecasted patient population of Cus...


Cushing Syndrome Market Insights, Epidemiology and Market Forecast 2023 EU5 [Updated: 30052017] Prices from USD $2083

DelveInsight's Cushing Syndrome Market Insights, Epidemiology and Market Forecast 2023 EU5 Reports provides an overview of the disease and global market size of the Cushing Syndrome for the EU5. It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Cushing Syndrome from 20102023. According to Publisher, the forecasted patient population of C...

Cushing's Syndrome Market Insights, Epidemiology and Market Forecast2023 [Updated: 30052017] Prices from USD $4208

DelveInsight's Cushing Syndrome Market Insights, Epidemiology and Market Forecast 2023 7MM Reports provides an overview of the disease and global market size of the Cushing Syndrome for the 7MM. It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Cushing Syndrome from 20102023. According to Publisher, the forecasted patient population of C...


NIH finding may lead to therapies that prevent Cushing syndrome

  A small study by researchers at the National Institutes of Health (NIH) suggests that mutations in the gene CABLES1 may lead to Cushing syndrome, a rare disorder in which the body overproduces the stress hormone cortisol. The study appears online in Endocrine-Related Cancer. The excess cortisol found in Cushing syndrome can result from certain […] The post NIH finding may lead to therapie...

Hair analysis may help diagnose Cushing Syndrome

Analyzing a hair sample may help with the diagnosis of Cushing Syndrome, a rare and potentially fatal disorder in which the body overproduces the stress hormone cortisol, according to researchers at the National Institutes of ... Read more

Hair Sample Might Aid in Cushing's Syndrome Diagnosis

A 1-cm hair sample closest to the scalp was found to be a potential marker for hypercortisolemia in patients suspected of having Cushing's syndrome. Medscape Medical News

Cushing's Syndrome Epidemiology Forecast To 2023 [Updated: 31052017] Prices from USD $2338

DelveInsight Cushing's Syndrome Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Cushing's Syndrome in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Cushing's Syndrome prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevaili...

Hair analysis may help diagnose Cushing syndrome, researchers report

Analyzing a hair sample may help with the diagnosis of Cushing Syndrome, a rare and potentially fatal disorder in which the body overproduces the stress hormone cortisol, according to researchers at the National Institutes of Health.

Medical News Today: Cushing's syndrome: Could analyzing hair confirm diagnosis?

Researchers from the National Institutes of Health find that cortisol levels detected in hair might be able to confirm a diagnosis of Cushing's syndrome.

Potential Genetic Cause of Cushing Syndrome Found

A recent study suggests that mutations in the gene Cdk5 And Abl Enzyme Substrate 1 (CABLES1) may lead to Cushing...

New NIH study reveals mutations in gene CABLES1 may lead to Cushing syndrome

A new study conducted by researchers at the National Institutes of Health (NIH) shows that mutations in the gene CABLES1 may lead to Cushing syndrome, a rare disorder that makes the human body produce excess stress hormone cortisol.

Corcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress

MENLO PARK, CA -- (Marketwired) -- 05/04/17 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that presentations about hypercortisolism and mifepristone's role in treating that disor...

Relevant

NIH researchers find potential genetic cause of Cushing syndrome

Finding may lead to therapies that prevent pituitary tumor recurrence.

Millendo Therapeutics Announces Initiation Of Phase II Clinical Trial Of ATR-101 In Patients With Endogenous Cushing???s Syndrome

  Life Sciences Jobs   ...

Hair Test for Cushing Syndrome?

(MedPage Today) -- Cortisol levels in hair correlated strongly with standard tests

Revised Commentary on Corcept's S-3 Registration - After Talking to Management

When we originally released our latest post on Corcept Therapeutics (CORT), we had not yet spoken to management.Explanation for S-3The recent S-3 filing for registering shares is a “just in case”. It is for raising money in the case an unexpected event. For example, if a clinical trial returns surprisingly good results, Corcept management may feel compelled to initiate a large clinical trial. ...

Hair analysis may help diagnose Cushing Syndrome, NIH researchers report

Small study suggests that high cortisol level in hair may foretell hard-to-diagnose disorder.

Why is Corcept Raising Capital? REVISED

When we originally released this post, we had not yet spoken to management. The recent S-3 filing for registering shares is a “just in case”. The older S-3 is expiring. The new S-3 covers unexpected program changes (e.g. surprisingly good results in a major indication). FO Charlie Robb confirmed what he stated in the latest conference call: As we have said in past calls, we believe revenu...

Millendo commences Phase II trial of ATR-101 to treat endogenous CS

US-based biopharmaceutical firm Millendo Therapeutics has commenced a Phase II clinical trial of ATR-101 for the treatment of patients with endogenous cushing’s syndrome (CS).

What's Behind Corcept's (CORT) Valuation Dip - June 8, 2017

On Thursday, June 8, 2017, Corcept Therapeutics (CORT) had a difficult trading day.  There were some large trades in the morning that sent the valuation careening from its previous close of $12.48 to just about 11.25. It closed at $11.51.Retail became concerned and rumor ran faster than a barking dog. But we have been waiting for this selling to occur. CORT had a valuation dip in late Novembe...

Why did Corcept's (CORT) Share Price Rise?

IntroductionWe recently fielded multiple inquiries about Corcept Therapeutics (CORT): what’s the reason(s) for its increased valuation?Recent Price ActionMay 1, 2017: Corcept released its Q1-2017 results and provided upward guidance for sales. The company also added $4M to its cash position while launching important new clinical studies. 

Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing’s Syndrome

Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases caused by hormone dysregulation, today announced the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of a novel oral drug

Why is Corcept Raising Capital?

As of the morning of March 14, 2017, the Nasdaq is down and also Corcept Therapeutics (CORT). Although there may be some profit taking, CORT’s dip may also be a reaction to the recent filing of its registration statement. As we have mentioned before, there are some investors who are interested in Corcept as an earnings story. Although Corcept derives sales revenues from a single indication, we t...

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance

MENLO PARK, CA -- (Marketwired) -- 03/06/17 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today reported financial results for the quarter- and ...

Cortisol excess hits natural DNA process and mental health hard

High concentrations of the stress hormone cortisol affect important DNA processes and increase the risk of long-term psychological consequences. These relationships are evident in a study from the Sahlgrenska Academy on patients with Cushing's syndrome, but the findings also open the door for new treatment strategies for other stress-related conditions such as anxiety, depression and post-traumati...


Quick Search
Advertisement
 

News Quicklinks